Systemic sclerosis: The susceptible host (genetics and environment)

Rheumatic Disease Clinics of North America

Volumn 29, Issue 2, 2003, Pages 211-237

  Tan, Filemon K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; FIBRILLIN; FIBRONECTIN; HLA ANTIGEN; HLA DR5 ANTIGEN; INTERLEUKIN 4; SILICON DIOXIDE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ALLELISM; BLOOD VESSEL REACTIVITY; DISEASE TRANSMISSION; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HETEROZYGOSITY; HUMAN; IMMUNOLOGICAL TOLERANCE; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS;

EID: 0037785169     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00015-2     Document Type: Review

References (224)

1. Barnett AJ. History of scleroderma. In: Barnett AJ, editor. History of Scleroderma. 1st edition. Baltimore: Williams and Wilkins; 1996. p. 3-22.
2. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Internat Rev Immunol 1995;12:107-28.
3. Mauch C, Eckes B, Hunzelmann N, et al. Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993;100:92S-6S.
4. Varga J, Bashey RI. Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 1995;12:187-99.
5. Kahaleh MB. The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy). Clin Exp Rheumatol 1992;10(Suppl 7):51-6.
6. Garabrant DH, Dumas C. Epidemiology of organic solvents and connective tissue disease. Arthritis Res 2000;2:5-15.
7. Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect 1999;107:743-8.
8. Steen VD. Occupational scleroderma. Curr Opin Rheumatol 1999;11:490-4.
9. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000;61:154-66.
10. Indulski JA, Lutz W. Metabolic genotype in relation to individual susceptibility to environmental carcinogens. Int Arch Occup Environ Health 2000;73:71-85.
11. Povey A, Guppy MJ, Wood M, et al. Cytochrome P2 polymorphisms and susceptibility to scleroderma following exposure to organic solvents. Arthritis Rheum 2001;44:662-5.
12. Tew MB, Reveille JD, Arnett FC, et al. Glutathione S-transferase genotypes in systemic sclerosis and their association with clinical manifestations in early disease. Genes Immun 2001;2:236-8.
13. McHugh NJ, Whyte J, Harvey G, et al. Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity. Arthritis Rheum 1994;37:1198-205.
14. Parks CG, Conrad K, Cooper GS. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 1999;107(Suppl 5):793-802.
15. Rustin MH, Bull HA, Ziegler V, et al. Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol 1990;123:725-34.
16. Englert H, Small-McMahon J, Davis K, et al. Male systemic sclerosis and occupational silica exposure-a population- based study. Aust N Z J Med 2000;30:215-20.
17. Silman AJ, Jones S. What is the contribution of occupational environmental factors to the occurrence of scleroderma in men? Ann Rheum Dis 1992;51:1322-4.
18. Burns CJ, Laing TJ, Gillespie BW, et al. The epidemiology of scleroderma among women: assessment of risk from exposure to silicone and silica. J Rheumatol 1996;23:1904-11.
19. Roberts-Thomson PJ, Jones M, Hakendorf P, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J 2001;31:220-9.
20. Baum H, Davies H, Peakman M. Molecular mimicry in the MHC: hidden clues to autoimmunity. Immunol Today 1996;17:64-70.
21. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment [comments]. Arthritis Rheum 1997;40:1823-8.
22. Gross D, Huber BT, Steere AC. Molecular mimicry and Lyme arthritis. Curr Dir Autoimmun 2001;3:94-111.
23. Neidhart M, Kuchen S, Distler O, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999;42:389-92.
24. Ferri C, Zakrzewska K, Longombardo G, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 1999;17:718-20.
25. Kasturi KN, Hatakeyama A, Spiera H, et al. Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J Exp Med 1995;181:1027-36.
26. Maul GG, Jimenez SA, Riggs E, et al. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci USA 1989;86:8492-6.
27. Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000;6:1183-6.
28. Bordron A, Dueymes M, Levy Y, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998;101:2029-35.
29. Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol 1999;120:169-76.
30. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
31. Tan FK, Arnett FC. Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 2000;12:511-9.
32. Maddison PJ, Stephens C, Briggs D, et al. Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. Medicine (Baltimore) 1993;72:103-12.
33. Englert H, Small-McMahon J, Chambers P, et al. Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999;29:36-41.
34. Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44:1359-62.
35. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996;85:311-8.
36. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
37. Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma. Arthritis Rheum 1996;39:1362-70.
38. Tan FK, Stivers DN, Arnett FC, et al. HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999;53:74-80.
39. Kuwana M, Kaburaki J, Arnett FC, et al. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-74.
40. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-46.
41. Gilchrist FC, Bunn C, Foley PJ, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001;2:76-81.
42. Kuwana M, Inoko H, Kameda H, et al. Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999;38:336-44.
43. Nelson JL. Microchimerism and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 1998;10:564-71.
44. Johnson KL, Nelson JL, Furst DE, et al. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001;44:1848-54.
45. Maloney S, Smith A, Furst DE, et al. Microchimerism of maternal origin persists into adult life. J Clin Invest 1999;104:41-7.
46. Lambert NC, Evans PC, Hashizumi TL, et al. Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. J Immunol 2000;164:5545-8.
47. Scaletti C, Vultaggio A, Bonifacio S, et al. Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum 2002;46:445-50.
48. Evans PC, Lambert N, Maloney S, et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999;93:2033-7.
49. Artlett CM, Cox LA, Jimenez SA. Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens. Arthritis Rheum 2000;43:1062-7.
50. Ichikawa N, Kotake S, Hakoda M, et al. Microchimerism in Japanese patients with systemic sclerosis. Arthritis Rheum 2001;44:1226-8.
51. Murata H, Nakauchi H, Sumida T. Microchimerism in Japanese women patients with systemic sclerosis [letter]. Lancet 1999;354:220.
52. Pisa FE, Bovenzi M, Romeo L, et al. Reproductive factors and the risk of scleroderma: an Italian case-control study. Arthritis Rheum 2002;46:451-6.
53. McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999;163:5693-9.
54. Yamamoto T, Takagawa S, Katayama I, et al. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999;92:6-13.
55. Cotton SA, Herrick AL, Jayson MI, et al. TGF beta-a role in systemic sclerosis? J Pathol 1998;184:4-6.
56. Falanga V, Gerhardt CO, Dasch JR, et al. Skin distribution and differential expression of transforming growth factor beta 1 and beta 2. J Dermatol Sci 1992;3:131-6.
57. Querfeld C, Eckes B, Huerkamp C, et al, Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci 1999;21:13-22.
58. Sfikakis PP, McCune BK, Tsokos M, et al. Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993;69:199-204.
59. Kulozik M, Hogg A, Lankat-Buttgereit B, et al. Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990;86:917-22.
60. Rudnicka L, Varga J, Christiano AM, et al. Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. Regulation by transforming growth factor-beta. J Clin Invest 1994;93:1709-15.
61. Corrin B, Butcher D, McAnulty BJ, et al. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-50.
62. Gabrielli A, Di Loreto C, Taborro R, et al. Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993;68:340-9.
63. Higley H, Persichitte K, Chu S, et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994;37:278-88.
64. Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
65. McWhirter A, Colosetti P, Rubin K, et al. Collagen type I is not under autocrine control by transforming growth factor-beta 1 in normal and scleroderma fibroblasts. Lab Invest 1994;71:885-94.
66. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998;95:737-40.
67. Chen SJ, Yuan W, Lo S, et al. Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 2000;183:381-92.
68. Chen SJ, Yuan W, Mori Y, et al. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 1999;112:49-57.
69. Ghosh AK, Yuan W, Mori Y, et al. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 2000;19:3546-55.
70. Mori Y, Chen SJ, Varga J. Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. Exp Cell Res 2000;258:374-83.
71. Afrakhte M, Moren A, Jossan S, et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 1998;249:505-11.
72. Ishisaki A, Yamato K, Nakao A, et al. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells. J Biol Chem 1998;273:24293-6.
73. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;389:631-5.
74. McGaha TL, Phelps RG, Spiera H, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-70.
75. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104:5-11.
76. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002;99:3908-13.
77. Ghosh AK, Yuan W, Mori Y, et al. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001;276:11041-8.
78. Zhou XD, Tan FK, Stivers DN, et al. Microsatellites and intragenic polymorphisms of transforming growth factor beta and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis: a preliminary genetic analysis showing no genetic association. Arthritis Rheum 2000;43:1068-73.
79. Susol E, Rands AL, Herrick A, et al. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatology. 2000;39:1332-6.
80. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
81. Bradham DM, Igarashi A, Potter RL, et al. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991;114:1285-94.
82. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 2002;4:136-42.
83. Holmes A, Abraham DJ, Sa S, et al. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001;276:10594-601.
84. Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol 1995;105:128-32.
85. Leask A, Sa S, Holmes A, et al. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol 2001;54:180-3.
86. Shi-Wen X, Pennington D, Holmes A, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000;259:213-24.
87. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995;105:280-4.
88. Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-50.
89. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000;27:149-54.
90. Blom IE, van Dijk AJ, de Weger RA, et al. Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. Mol Pathol 2001;54:192-6.
91. Bolster MB, Ludwicka A, Sutherland SE, et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997;40:743-51.
92. Gruschwitz MS, Albrecht M, Vieth G, et al. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997;24:1936-43.
93. Hasegawa M, Fujimoto M, Kikuchi K, et al. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997;24:663-5.
94. Kantor TV, Friberg D, Medsger TA, et al. Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992;65:278-85.
95. Takeda K, Hatamochi A, Arakawa M, et al. Effects of tumor necrosis factor-alpha on connective tissue metabolism in normal and scleroderma fibroblast cultures. Arch Dermatol Res 1993;284:440-4.
96. Abraham DJ, Shiwen X, Black CM, et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-5.
97. Field M. Tumour necrosis factor polymorphisms in rheumatic diseases. QJM 2001;94:237-46.
98. Pandey JP, Takeuchi F. TNF-alpha and TNF-beta gene polymorphisms in systemic sclerosis. Hum Immunol 1999;60:1128-30.
99. Takeuchi F, Nabeta H, Fussel M, et al. Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 2000;59:293-6.
100. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:224-31.
101. Kuwana M, Inoko H, Kameda H, et al. Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999;38:336-44.
102. Kuwana M, Kaburaki J, Okano Y, et al. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993;92:1296-301.
103. Ong C, Wong C, Roberts CR, et al. Anti-IL-4 treatment prevents dermal collagen deposition in the tight- skin mouse model of scleroderma. Eur J Immunol 1998;28:2619-29.
104. Atamas SP, Yurovsky VV, Wise R, et al. Production of type 2 cytokines by CD8 + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis [comments]. Arthritis Rheum 1999;42:1168-78.
105. Lee KS, Ro YJ, Ryoo YW, et al. Regulation of interleukin-4 on collagen gene expression by systemic sclerosis fibroblasts in culture. J Dermatol Sci 1996;12:110-7.
106. Serpier H, Gillery P, Salmon-Ehr V, et al. Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997;109:158-62.
107. Salmon-Ehr V, Serpier H, Nawrocki B, et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 1996;132:802-6.
108. Hasegawa M, Fujimoto M, Kikuchi K, et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32.
109. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma [comments]. Arthritis Rheum 1992;35:67-72.
110. Sakkas LI, Tourtellotte C, Berney S, et al. Increased levels of alternatively spliced interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis [comments]. Clin Diagn Lab Immunol 1999;6:660-4.
111. Majumdar S, Li D, Ansari T, et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14:251-7.
112. Kanemitsu S, Takabayashi A, Sasaki Y, et al. Association of interleukin-4 receptor and interleukin-4 promoter gene polymorphisms with systemic lupus erythematosus. Arthritis Rheum 1999;42:1298-300.
113. Rosenwasser LJ. Promoter polymorphism in the candidate genes, IL-4, IL-9, TGF-beta1, for atopy and asthma. Int Arch Allergy Immunol 1999;118:268-70.
114. Youn J, Hwang SH, Cho CS, et al. Association of the interleukin-4 receptor alpha variant Q576R with Th1/Th2 imbalance in connective tissue disease. Immunogenetics 2000;51:743-6.
115. Southcott AM, Jones KP, Li D, et al. Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 1995;151:1604-12.
116. Renzoni E, Lympany P, Sestini P, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000;43:1633-40.
117. Jimenez SA, Gershwin ME. Animal models of systemic sclerosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 1st edition. Baltimore: Williams and Wilkins; 1996. p. 251-73.
118. Phelps RG, Daian C, Shibata S, et al: Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun 1993;6:701-18.
119. Wallace VA, Kondo S, Kono T, et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994;24:1463-6.
120. Kasturi KN, Hatakeyama A, Murai C, et al. B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene. J Autoimmun 1997;10:505-17.
121. Siracusa LD, McGrath R, Fisher JK, et al. The mouse tight skin (Tsk) phenotype is not dependent on the presence of mature T and B lymphocytes. Mamm Genome 1998;9:907-9.
122. McGaha T, Saito S, Phelps RG, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001;116:136-43.
123. Dallas SL, Keene DR, Bruder SP, et al. Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res 2000;15:68-81.
124. Dallas SL, Miyazono K, Skerry TM, et al. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995;131:539-49.
125. Sinha S, Nevett C, Shuttleworth CA, et al. Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. Matrix Biol 1998;17:529-45.
126. McKenzie SE, Mansfield E, Rappaport E, et al. Parallel molecular genetic analysis. Eur J Hum Genet 1998;6:417-29.
127. Raghunath M, Unsold C, Kubitscheck U, et al. The cutaneous microfibrillar apparatus contains latent transforming growth factor-beta binding protein-1 (LTBP-1) and is a repository for latent TGF-beta1. J Invest Dermatol 1998;111:559-64.
128. Taipale J, Miyazono K, Helkin CH, et al. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 1994;124:171-81.
129. Taipale J, Saharinen J, Hedman K, et al. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem 1996;44:875-89.
130. Bona CA, Murai C, Casares S, et al. Structure of the mutant fibrillin-1 gene in the tight skin mouse. DNA Res 1997;4:267-71.
131. Siracusa LD, McGrath R, Ma Q, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996;6:300-13.
132. Kielty C, Raghunath M, Siracusa LD, et al. The tight skin mouse: demonstration of mutant, fibrillin-1 production and assembly into abnormal microfibrils. J Cell Biol 1998;140:1159-66.
133. Gayraud B, Keene DR, Sakai LY, et al. New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse. J Cell Biol 2000;150:667-80.
134. Saito S, Nishimura H, Brumeanu TD, et al. Characterization of mutated protein encoded by partially duplicated fibrillin-1 gene in tight skin (TSK) mice. Mol Immunol 1999;36:169-76.
135. Taipale J, Koli K, Keski-Oja J. Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem 1992;267:25378-84.
136. Taipale J, Lohi J, Saarinen J, et al. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995;270:4689-96.
137. Denton CP, Zheng B, Shiwen X, et al. Activation of a fibroblast-specific enhancer of the proalpha2(I) collagen gene in tight-skin mice. Arthritis Rheum 2001;44:712-22.
138. Pablos JL, Everett ET, Harley R, et al. Transforming growth factor-beta 1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse. Lab Invest 1995;72:670-8.
139. Davis EC, Blattel SA, Mecham RP. Remodeling of elastic fiber components in scleroderma skin. Connect Tissue Res 1999;40:113-21.
140. Fleischmajer R, Jacobs L, Schwartz E, et al. Extracellular microfibrils are increased in localized and systemic scleroderma skin. Lab Invest 1991;64:791-8.
141. Tan FK, Stivers DN, Foster MW, et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998;41:1729-37.
142. Tan FK, Wang N, Kuwana M, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001;44:893-901.
143. Wallis DD, Tan FK, Kielty CM, et al. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001;44:1855-64.
144. Murai C, Saito S, Kasturi KN, et al. Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight skin mice. Autoimmunity 1998;28:151-5.
145. Tan FK, Arnett FC, Antohi S, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999;163:1066-72.
146. Tan FK, Arnett FC, Reveille JD, et al. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000;43:2464-71.
147. Varga J, Jimenez SA. Pathogenesis of scleroderma: cellular aspects. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 1st edition. Baltimore: Williams and Wilkins; 1996. p. 123-51.
148. Karsenty G, Park RW. Regulation of type I collagen genes expression. Int Rev Immunol 1995;12:177-85.
149. Artlett CM, Chen SJ, Varga J, et al. Modulation of basal expression of the human alpha1(I) procollagen gene (COL1A1) by tandem NF-1/Sp1 promoter elements in normal human dermal fibroblasts. Matrix Biol 1998;17:425-34.
150. Galera P, Musso M, Ducy P, et al. c-Krox, a transcriptional regulator of type I collagen gene expression, is preferentially expressed in skin. Proc Natl Acad Sci USA 1994;91:9372-6.
151. Saitta B, Gaidarova S, Cicchillitti L, et al. CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts. Arthritis Rheum 2000;43:2219-29.
152. Hitraya EG, Varga J, Artlett CM, et al. Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 1998;41:2048-58.
153. Ihn H, Tamaki K. Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. Arthritis Rheum 2000;43:2240-7.
154. Feghali CA, Wright TM. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 1999;42:1451-7.
155. Strehlow D, Jelaska A, Strehlow K, et al. A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma. J Clin Invest 1999;103:1179-90.
156. Hata R, Akai J, Kimura A, et al. Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Commun 2000;272:36-40.
157. Bou-Gharios G, Osman J, Black C, et al. Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. Clin Chim Acta 1994;231:69-78.
158. Brady AH. Collagenase in scleroderma. J Clin Invest 1975;56:1175-80.
159. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997;289:567-72.
160. Yazawa N, Kikuchi K, Ihn H, et al. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol 2000;42:70-5.
161. Young-Min SA, Beeton C, Laughton R, et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001;60:846-51.
162. Takeda K, Hatamochi A, Ueki H, et al. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994;103:359-63.
163. Johnson RW, Reveille JD, McNeamey T, et al. Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma). Genes Immun 2001;2:273-5.
164. Marasini B, Casari S, Zeni S, et al. Stromelysin promoter polymorphism is associated with systemic sclerosis. Rheumatology 2001;40:475-6.
165. Hawley ME, Kidd KK. A simple program that tests Hardy Weinberg ratios when sample sizes are small. 1995. Available at: http://krunch.med.yale.edu/hwsim/.
166. Rennard SI, Hunninghake GW, Bitterman PB, et al. Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci USA 1981;78:7147-51.
167. Esparza J, Vilardell C, Calvo J, et al. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 1999;94:2754-66.
168. Saito S, Yamaji N, Yasunaga K, et al. The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism. J Biol Chem 1999;274:30756-63.
169. Cooper SM, Keyser AJ, Beaulieu AD, et al. Increase in fibronectin in the deep dermis of involved skin in progressive systemic sclerosis. Arthritis Rheum 1979;22:983-7.
170. Fleischmajer R, Dessau W, Timpl R, et al. Immunofluorescence analysis of collagen, fibronectin, and basement membrane protein in scleroderma skin. J Invest Dermatol 1980;75:270-4.
171. Chen ZY, Maricq HR, Pilia PA, et al. Fibronectin distribution in nailfold biopsies of scleroderma (systemic sclerosis) patients. Acta Derm Venereol 1985;65:185-9.
172. Fleischmajer R, Perlish JS, Krieg T, et al. Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol 1981;76:400-3.
173. Eckes B, Mauch C, Huppe G, et al. Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma. Biochem J 1996;315:549-54.
174. Kinsella MB, Smith EA, Miller KS, et al. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum 1989;32:577-83.
175. Rennard SI, Crystal RG. Fibronectin in human bronchopulmonary lavage fluid. Elevation in patients with interstitial lung disease. J Clin Invest 1982;69:113-22.
176. Avila JJ, Lympany PA, Pantelidis P, et al. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999;20:106-12.
177. Deguchi Y, Negoro S, Kishimoto S. Mutant fibronectin gene in skin fibroblasts of sclerotic lesions from patients with progressive systemic sclerosis. Arthritis Rheum 1989;32:247-50.
178. Shiokawa S, Yasuda M, Nobunaga M. Unsuccessful search for mutant fibronectin genes in patients with systemic sclerosis. Arthritis Rheum 1990;33:1868-70.
179. Verheijen R, Oberye EH, van den Hoogen FH, et al. The mutations in the fibronectin gene described in Japanese patients with systemic sclerosis are not present in Dutch patients. Arthritis Rheum 1991;34:490-2.
180. Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566-71.
181. Tabata H, Yamakage A, Yamazaki S. Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 1997;36:272-5.
182. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-25.
183. Xu S, Denton CP, Holmes A, et al. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998;31(Suppl 1):S360-3.
184. Xu SW, Denton CP, Dashwood MR, et al. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998;31(Suppl 1):S545-7.
185. Romero LI, Zhang DN, Cooke JP, et al. Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 2000;5:147-58.
186. Cotton SA, Herrick AL, Jayson MI, et al. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999;189:273-8.
187. Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998;25:314-7.
188. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
189. Rigat B, Hubert C, Corvol P, et al. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992;20:1433.
190. Matucci-Cerinic M, Pignone A, Iannone F, et al. Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respir Med 1990;84:283-7.
191. Matucci-Cerinic M, Pignone A, Lotti T, et al. Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? J Rheumatol 1990;17:328-30.
192. Smyth AE, Hughes AE, Bruce IN, et al. A case-control study of candidate vasoactive mediator genes in primary Raynaud's phenomenon. Rheumatology (Oxford) 1999;38:1094-8.
193. Mayer NJ, Forsyth A, Kantachuvesiri S, et al. Association of the D allele of the angiotensin I converting enzyme polymorphism with malignant vascular injury. Mol Pathol 2002;55:29-33.
194. Kahaleh MB. Vascular disease in scleroderma. Endothelial T lymphocyte-fibroblast interactions. Rheum Dis Clin North Am 1990;16:53-73.
195. Leroy EC. Pathogenesis of scleroderma (systemic sclerosis). J Invest Dermatol 1982;79(Suppl 1):87s-9s.
196. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthritis Rheum 1991;34:1495-501.
197. Gruschwitz M, von den Driesch P, Kellner I, et al. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992;27:169-77.
198. Kraling BM, Jimenez SA, Sorger T, et al. Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 1994;71:745-54.
199. Carvalho D, Savage CO, Black CM, et al. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996;97:111-9.
200. Hill MB, Phipps JL, Cartwright RJ, et al. Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 1996;106:491-7.
201. Kahaleh MB, Fan PS. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997;83:32-40.
202. Kahaleh MB, Fan PS, Otsuka T. Gammadelta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 1999;91:188-95.
203. Meyer O, Haim T, Dryll A, et al. Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol 1983;1:29-34.
204. Ihn H, Sato S, Fujimoto M, et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000;119:203-9.
205. Pignone A, Scaletti C, Matucci-Cerinic M, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998;16:527-32.
206. Renaudineau Y, Grunebaum E, Krause I, et al. Anti-endothelial cell antibodies (AECA) in systemic sclerosis - increased sensitivity using different endothelial cell substrates and association with other autoantibodies. Autoimmunity 2001;33:171-9.
207. Lima J, Fonollosa V, Fernandez-Cortijo J, et al. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991;18:1833-6.
208. Merkel PA, Chang Y, Pierangeli SS, et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576-83.
209. Nguyen VA, Sgonc R, Dietrich H, et al. Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (scleroderma). J Autoimmun 2000;14:143-9.
210. Sgonc R, Gruschwitz MS, Boeck G, et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody- dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000;43:2550-62.
211. Belizna C, Tervaert JW. Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies. Semin Arthritis Rheum 1997;27:98-109.
212. Black CM, du Bois RM. Organ involvement: pulmonary. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 1st edition. Baltimore: Williams and Wilkins; 1996. p. 299-331.
213. Morse JH, Deng Z, Knowles JA. Genetic aspects of pulmonary arterial hypertension. Ann Med 2001;33:596-603.
214. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4.
215. Tew MB, Arnett FC, Reveille JD, et al. Mutations of bone morphogenetic protein receptor 2 (BMPR2) are not found in patients with primary pulmonary hypertension and underlying connective tissue disease. Arthritis Rheum 2002;46:2829-30.
216. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-34.
217. Becker KG, Simon RM, Bailey-Wilson JE, et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998;95:9979-84.
218. Schaid DJ. Transmission disequilibrium, family controls, and great expectations. Am J Hum Genet 1998;63:935-41.
219. Long AD, Langley CH. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res 1999;9:720-31.
220. Morton NE, Collins A. Tests and estimates of allelic association in complex inheritance. Proc Natl Acad Sci USA 1998;95:11389-93.
221. Delvin B, Roeder K. Genomic control for association studies. Biometrics 1999;55:997-1004.
222. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-8.
223. Pritchard JK, Stephens M, Rosenberg NA, et al. Association mapping in structured populations. Am J Hum Genet 2000;67:170-81.
224. Fatini C, Gensini F, Sticchi E, et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 2002;112:540-4.